From lab to scale: The coordination layer for modern bio-manufacturing.
Cambridge, MA
Joined May 2026
- Tweets51
- Following434
- Followers49
- Likes224
Pinned Tweet
Everyone loves innovation.
Fewer people talk about what it takes to actually manufacture it.
In biotech, the future isn’t just discovered. It has to be built.
#biotech #pharma #CDMO #manufacturing
CDMO Network retweeted
siRNA dominates the cardiometabolic RNA field
We mapped ~85 active programs from 48 companies targeting 9 popular cardiometabolic pathways (about ~40% of the total active pipeline). ~92% of programs are siRNA, versus just 8% ASO.
That concentration is mostly due to delivery. GalNAc has made liver delivery efficient / repeatable, and every target on this map is largely produced there.
Once this core delivery platform is in place, a company can swap the RNA sequence fairly easily. So clinical validation leads to fast followers: for 7/9 of these pathways, programs have already reached Ph3 or beyond.
That crowding is making durability, convenience (2x / year is increasingly the entry ticket) and outcomes data much more important to differentiate.
And just showing activity ≠ a meaningful clinical benefit waits on the other side:
• Most recently, Novartis' Pelacarsen lowered Lp(a) but did not reduce CV events in an 8K+ patient Ph3
• AZ / Ionis' Eplontersen reduced TTR but missed overall Ph3 primary endpoint in ATTR-CM
• Ionis' Olezarsen reduced TG by 64% and remnant cholesterol by 72%, but did not change non-calcified coronary plaque at 12 months
All of these are ASO readouts, which mostly highlights that it's a more mature modality that reached outcomes-stage testing earlier. siRNA programs will face the same question: does deep, durable knockdown actually produce a benefit on top of modern standard of care?
Looking ahead, the next battleground is 'extrahepatic' delivery (reaching the heart, muscle, CNS and other tissues beyond the liver), just one topic we'll cover in far more depth tomorrow when we drop a 15+ slide report on the RNA space.
In the meantime, comment below if you'd like a hi-res PDF of this map!
CDMO Network retweeted
This is super cool!
@garykbrixi and @_David_Li use genome language models to discover a new class of reverse transcriptase, incredible!
Genomes are full of dark matter of unknown functions.
We present Minerva, a new method for discovery guided by genome language models. Minerva reveals the interactions hidden in non-coding DNA, pointing to hundreds of new putative RNAs and repetitive elements per bacterial genome. Minerva allows us to find and study elements invisible to traditional methods at orders of magnitude greater scale than before.
CDMO Network retweeted
Can AI spark a second industrial revolution in Europe?
@Siftedeu says it’s already generating new knowledge and insight — and features @Basecamp_Res as an example.
We’re using AI to read the language of DNA from 1M+ new species to power the next generation of cures.
Sifted Pro Subscribers can read the column here: sifted.eu/articles/ai-second…
#AI #Biotech #BasecampResearch
This is the architecture we’re building toward: specialized CDMO capability, connected around the program—not trapped inside one organization.
#CDMO #Biomanufacturing #Biotech
The future of biotech belongs to companies that can orchestrate science, manufacturing, capital, data and AI around the asset.
That is the Open Ecosystem.
Read more: berubebioventures.com/open-b…
#Biotech #Biopharma #CDMO #AI
ALT Elegant biotech banner reading “Why Biotechnology Advances Through Structured Non-Closure,” with large navy and teal serif typography on a clean white background, flowing layered teal geometric forms, and a partially open spherical molecular structure containing interconnected cells and network nodes, symbolizing biotechnology as an open, relational ecosystem.
CDMO Network retweeted
Anti-cancer progress
Japanese Scientists just found a living bacterium from a frog's gut that eliminated 100% colon cancer after a single treatment.
"Researchers at JAIST discovered a naturally occurring bacterium called Ewingella americana from the gut of the Japanese tree frog (Dryophytes japonicus). A single intravenous injection produced a 100% complete response, eliminating colorectal tumors in every treated mouse."
"The bacterium accumulated about 3,000-fold inside tumors within 24 hours, directly killing cancer cells while activating CD4⁺ T cells, CD8⁺ T cells, B cells, neutrophils, TNF-α, and IFN-γ to generate a powerful antitumor immune response."
"E. americana also didn't colonize healthy organs such as the liver, lungs, or kidneys and treated mice experienced only mild, temporary inflammation over a 60-day observation period with zero systemic toxicity."
"When scientists injected the same cancer cells again, 0 out of 10 cured mice developed tumors, suggesting long-lasting immune memory. The therapy now awaits further validation in larger animal studies and human clinical trials."
Awesome! We love to see AI progress in #peptide design.
BIG BREAKTHROUGH:
Quantum computing just took a meaningful step into real-world biology.
"Danish scientists combined a photonic quantum computer with generative AI to design vaccine peptides, then validated the results in the lab."
"Across 131 HLA types, the hybrid system generated stronger peptide candidates than classical AI for 63% of them, with its greatest advantage appearing when training data were scarce."
"This suggests hybrid Quantum + AI could help accelerate vaccine development, personalized immunotherapy and drug discovery for diseases that currently lack sufficient biological data."
Ai diffusion is unstoppable!
CDMO Network retweeted
This is big. Really big.
Researchers from Google Quantum Al and Google DeepMind developed an Al system that continuously keeps Google's 105-qubit Willow quantum processor optimized while it is running.
"Instead of stopping for manual recalibration, the Al uses reinforcement learning to monitor quantum error correction and automatically adjust hardware control parameters in real time."
"The system improved logical stability by 3.5x under hardware drift and achieved a record logical error rate of 7.72 × 10⁻⁴ per cycle for the surface code."
"This is an important step toward future fault-tolerant quantum computers that can operate autonomously for long periods with minimal human intervention."
What is a CDMO?
The simple answer: a Contract Development and Manufacturing Organization.
The better answer?
Read more to find out —> cdmonetwork.com/what-is-a-cd…
#CDMO #Biopharma #Biotech #CRO #Pharma #Biologics #ViralVectors – at Boston, MA
ALT Has CDMO Network logo then text says “Looking for a CDMO? CDMO Network does your search for free. Contact our team today at [email protected]
CDMO Network retweeted
🚨 The widely used sugar alternative erythritol could be sabotaging your health.
A new study shows it erodes the blood-brain barrier and inhibits the body's natural ability to dissolve blood clots.
A new study from the University of Colorado suggests that erythritol, a sugar alcohol common in keto-friendly and sugar-free snacks, may directly damage the blood-brain barrier. By exposing cells to levels typically found after consuming a single sweetened beverage, researchers observed a spike in oxidative stress and the death of critical cells responsible for guarding the brain against toxins. This disruption shifts the body’s delicate chemical balance by reducing nitric oxide and increasing endothelin-1, causing blood vessels to constrict dangerously and potentially starving the brain of essential oxygen and nutrients.
Beyond physical vessel damage, the sweetener appears to sabotage the body’s innate defense against strokes by blocking the release of tissue plasminogen activator—a natural "clot-buster" that dissolves blockages before they can trigger a medical emergency. These laboratory findings align with large-scale human observational data showing that individuals with high erythritol levels are twice as likely to experience major cardiac events. While regulatory agencies currently deem the sweetener safe, these results prompt a serious re-evaluation of the long-term health trade-offs associated with popular sugar substitutes.
Source: Chichger, H. (2026). Common Sweetener May Damage Critical Brain Barrier, Risking Stroke. The Conversation.
ALT 🚨 The widely used sugar alternative erythritol could be sabotaging your health. A new study shows it erodes the blood-brain barrier and inhibits the body's natural ability to dissolve blood clots. A new study from the University of Colorado suggests that erythritol, a sugar alcohol common in keto-friendly and sugar-free snacks, may directly damage the blood-brain barrier. By exposing cells to levels typically found after consuming a single sweetened beverage, researchers observed a spike in oxidative stress and the death of critical cells responsible for guarding the brain against toxins. This disruption shifts the body’s delicate chemical balance by reducing nitric oxide and increasing endothelin-1, causing blood vessels to constrict dangerously and potentially starving the brain of essential oxygen and nutrients. Beyond physical vessel damage, the sweetener appears to sabotage the body’s innate defense against strokes by blocking the release of tissue plasminogen activator.
Cool!
Stanford Medicine researchers have found that two proteins with opposing functions orchestrate healthy skin development and maintenance. Modulating their activity with topical drugs could reduce inflammation, aid wound healing, and slow or halt the growth of skin cancer. med.stanford.edu/news/all-ne…
Nuance in here might be that GLP-1 receptor agonists are filling a missing piece in the human body; and that obesity prevention through biopharmaceutical interventions have a domino effect on public health.
GLP-1 receptor agonists (GLP-1 RAs) are associated with reduced incidence of breast cancer among women with overweight or obesity, according to two observational studies.
One found that GLP-1 RA users had a roughly 30% lower incidence of breast cancer than was seen in matched nonusers. The smaller of the two, which followed more than 80,000 women at high risk for breast cancer, found a more modest 16% reduction.
Using GLP-1 drugs to prevent cancer is “an exciting new frontier that will likely revolutionize the field of oncology, but like any new exciting therapy we need [randomized] clinical trials to understand how to optimally” use them, said Neil M. Iyengar, MD, a breast medical oncologist who was not involved in either study. mdsc.pe/4f1zkLT
CDMO Network retweeted
I had a philosophy idea that gaps, asymmetries, fantasy, and relation govern the world more than logic, objects, and symmetry.
I decided, once, to truly embody that philosophy.
Almost immediately, it became a business: a biotech infrastructure company, a CDMO routing network, and a funnel with over $2B in lifecycle value in just 10months.
All built by myself — with systems thinking, design, poetry, fantasy, and even some logic.
When in doubt of your philosophy, take the next step.
Become it.
#biotech #biopharma #pharma #CDMO #entrepreneurship #venturecapital #VC #founders #business #leadership
CDMO Network retweeted
Scientists just published the first comprehensive atlas of human cellular senescence in aging.
They are mapping where "zombie cells" appear in the human body, how they differ across tissues, and how they interact with their surrounding environment.
These cells stop dividing, but don’t die. Over time, they can accumulate and release inflammatory signals that damage nearby tissue, a process linked to arthritis, cancer, Alzheimer’s, immune decline, and other age-related diseases.
For medicine, this could be huge.
Instead of treating aging as a vague biological decline, researchers may be able to identify which senescent cell types are harmful, where they are located, and how to target them more precisely.
That could accelerate a new class of longevity therapies: not just extending lifespan. Love to see it!
CDMO Network retweeted
let’s fast forward to 2032 where generic semaglutide has flooded the UK and US markets, bringing the price down to around ~$60 and making mass adoption reasonable.
& then, of course, you have $LLY's best-in-class drugs delivering 25–30% weight loss while going for a clean sweep of indications, including knee osteoarthritis, IBD, asthma and potentially substance use disorder.
in that world, which is frighteningly close, how does a new obesity drug even compete?
it'll be exceedingly difficult. but what if genetics could help you identify patients who are more likely to respond to your drug, or more likely to experience side effects on a competitor’s?
that's a pretty compelling marketing wedge, and that is what I wanted to understand.
so, I spoke to @adamauton, VP of Human Genetics at @23andMe and a senior author of a first-of-its-kind Nature paper on the genetic predictors of GLP- 1 response.
it's been one of my favourite conversations so far.
we nerded out on:
• what obesity polygenic risk scores tell us about weight loss and weight regain
• why GLP1R and GIPR variants are associated with nausea and vomiting
• whether genetics could inform personalised titration
• whether our DNA might predict weight regain after stopping treatment
• how pharma companies could use genetics to define a drug’s target demographic
📌full breakdown below
$HIMS $LLY $NVO
VHH nanobody CDMO selection depends on format, expression system, analytics, GMP needs, and final product use.
New CDMO Network guide:
Best VHH Nanobody CDMO Services
Learn more: cdmonetwork.com/best-vhh-nan…
#VHH #Nanobody #CDMO #Biologics
CDMO Network retweeted
We’re building CDMO Network, CMC Infrastructure, and biotech commercialization platforms.
Only good things from here.
#berubebioventures #biopharma #VC
CDMO Network retweeted
Welcome to AI biotech era.
The is the new normal for late 2020s.
All kind of research, from years to seconds.
China has unveiled an artificial intelligence platform for drug discovery that can screen a vast library of chemical compounds, cutting the initial drug screening phase from months or years down to 10s of seconds.
